Table 1 Ages and treatment allocation of interviewed patients in randomised breast cancer trials (protocols Danish Breast Cancer Cooperative Group (DBCG) 89b and DBCG 89d) and in a randomised trial of advanced ovarian cancer.

		Treatment allocation in randomised cancer trials
		Breast cancer				Ovarian cancer
		DBCG 89b‐trial		DBCG 89d‐trial		TC/TEC‐trial
Patients	Age (years)	CMF	CEF	CMF	Ovarian radiation	TC	TEC
Patients participating in trial
Patient 1*	51				X
Patient 2*	58		X
Patient 3*	45		X
Patient 4*	48		X
Patient 5*	51		X
Patient 6*	50	X
Patient 7*	51	X
Patient 8†	48	X
Patient 9†	54		X
Patients declining trial
Patient 10*	51			X
Patient 11*	49				X
Patient 12*	44				X
Patient 13*	49				X
Patient 14*	43				X
Patient 15*	38				X
Patient 16*	50			X	X
Patient 17*	45	X
Patient 18*	62	X
Patient 19*	50	X
Patient 20*	51	X
Patient 21*	51	X
Patient 22*	44	X
Patient 23*	43	X
Patient 24*	41	X
Ovarian cancer
Patient 25‡	49						X
Patient 26‡	50						X
Patient 27‡	58						X
Patient 28‡	51					X
Patient 29‡	58					X

CEF, chemotherapy with cyclophosphamide/epirubicine/floururacile; CMF, chemotherapy with cyclophosphamide/methotrexate/floururacile; DBCG, Danish Breast Cancer Cooperative Group; DBCG 89b, randomised therapeutic trial, eligible patients with premenopausal breast cancer who were oestrogen‐receptor positive; DBCG 89d, randomised therapeutic trial, eligible patients with premenopausal breast cancer who were oestrogen‐receptor negative; TC, chemotherapy with paclitaxele/carboplatine; TEC, chemotherapy with paclitaxele/epirubicine/carboplatine.

Patients with breast cancer: trial participants (median age 51 years); trial decliners (median age 49 years). Patients with advanced ovarian cancer: trial participants (median age 51 years).

*Patients treated at the oncological department at Herlev University Hospital.

†Patients treated at the oncological department at Odense University Hospital.

‡Patients treated at the oncological department at Soenderborg Hospital.